How long to wait before reducing antipsychotic dosage in stabilized patients with schizophrenia? A retrospective chart review

Journal of Psychiatric Research

Volumn 45, Issue 8, 2011, Pages 1083-1088

  Takeuchi, Hiroyoshi ^a   Suzuki, Takefumi ^a,b,d   Uchida, Hiroyuki ^a,b   Kikuchi, Toshiaki ^a   Nakajima, Shinichiro ^a   Manki, Hiroshi ^a,c   Watanabe, Koichiro ^a   Kashima, Haruo ^a  

^a KEIO UNIVERSITY   (Japan)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c Komagino Hospital   (Japan)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotics; Dose reduction; Schizophrenia; Timing; Waiting period

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BROMPERIDOL; CHLORPROMAZINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ACUTE PSYCHOSIS; ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 79960578098     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2011.01.007     Document Type: Article

References (42)

1. Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, American Psychiatric Association, Washington, DC. 4th ed.
2. Argo T.R., Crismon M.L., Miller A.L., Moore T.A., Bendele S.D., Suehs B. Texas medication algorithm project procedural manual schizophrenia treatment algorithms 2008, http://www.dshs.state.tx.us/mhprograms/pdf/SchizophreniaManual_060608.pdf.
3. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin 2010, 36:71-93.
4. Clinical practice guidelines. Treatment of schizophrenia. Canadian Journal of Psychiatry 2005, 50(Suppl. 1):7S-57S. Canadian Psychiatric Association.
5. Cookson I.B. The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. International Clinical Psychopharmacology 1987, 2:141-149.
6. Correll C.U., Schenk E.M. Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry 2008, 21:151-156.
7. Dale R., Longdon M., Seeman M.V. Reducing the dose of depot neuroleptics in stable schizophrenia. Journal of Psychiatry & Neuroscience 1994, 19:278-281.
8. De Hert M., Correll C.U., Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophrenia Research 2010, 117:68-74.
9. Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., Möller H.J. WFSBP task force on treatment guidelines for schizophrenia. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World Journal of Biological Psychiatry 2006, 7:5-40.
10. Faraone S.V., Curran J.P., Laughren T., Faltus F., Johnston R., Brown W.A. Neuroleptic bioavailability, psychosocial factors, and clinical status: a 1-year study of schizophrenic outpatients after dose reduction. Psychiatry Research 1986, 19:311-322.
11. Faraone S.V., Green A.I., Brown W., Yin P., Tsuang M.T. Neuroleptic dose reduction in persistently psychotic patients. Hospital & Community Psychiatry 1989, 40:1193-1195.
12. Haddad P.M., Sharma S.G. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007, 21:911-936.
13. Hogarty G.E., Mcevoy J.P., Munetz M., Dibarry A.L., Bartone P., Cather R., et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. Archives of General Psychiatry 1988, 45:797-805.
14. Inagaki A., Inada T. Dose equivalence of psychotropic drugs. Part XVIII: dose equivalence of psychotropic drugs: 2006 - Version. Japanese Journal of Clinical Psychopharmacology 2006, 9:1443-1447.
15. Inderbitzin L.B., Lewine R.R., Scheller-Gilkey G., Swofford C.D., Egan G.J., Gloersen B.A., et al. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. American Journal of Psychiatry 1994, 151:1753-1759.
16. International psychopharmacology algorithm project schizophrenia algorithm 2004, http://www.ipap.org/pdf/schiz/IPAP_Schiz_nodenotes.pdf.
17. Johnson D.A., Ludlow J.M., Street K., Taylor R.D. Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. British Journal of Psychiatry 1987, 151:634-638.
18. Kane J.M., Leucht S., Carpenter D., Docherty J.P. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. Journal of Clinical Psychiatry 2003, 64(Suppl. 12):5-19.
19. Kane J.M., Rifkin A., Woerner M., Reardon G., Sarantakos S., Schiebel D., et al. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry 1983, 40:893-896.
20. Kawai N., Yamakawa Y., Baba A., Nemoto K., Tachikawa H., Hori T., et al. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction. Progress in Neuro-psychopharmacology & Biological Psychiatry 2006, 30:1009-1014.
21. Kreisman D., Blumenthal R., Borenstein M., Woerner M., Kane J., Rifkin A., et al. Family attitudes and patient social adjustment in a longitudinal study of outpatient schizophrenics receiving low-dose neuroleptics: the family's view. Psychiatry 1988, 51:3-13.
22. Leblanc G., Cormier H., Gagne M.A., Vaillancourt S. Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses. Canadian Journal of Psychiatry 1994, 39:223-229.
23. Lehman A.F., Lieberman J.A., Dixon L.B., Mcglashan T.H., Miller A.L., Perkins D.O., et al. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. American Journal of Psychiatry 2004, 161(Suppl. 2):1-56.
24. Leucht S., Barnes T.R., Kissling W., Engel R.R., Correll C., Kane J.M. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. American Journal of Psychiatry 2003, 160:1209-1222.
25. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
26. Lipkovich I., Baron D., Houston J., Ahl J., Rotelli M. Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments. Journal of Clinical Psychopharmacology 2005, 25:381-386.
27. Core interventions in the treatment and management of schizophrenia in primary and secondary care (update) 2009, National Institute for Health and Clinical Excellence. http://guidance.nice.org.uk/CG82/NICEGuidance/pdf/English.
28. Olfson M., Marcus S.C., Corey-Lisle P., Tuomari A.V., Hines P., L'italien G.J. Hyperlipidemia following treatment with antipsychotic medications. American Journal of Psychiatry 2006, 163:1821-1825.
29. Ray W.A., Chung C.P., Murray K.T., Hall K., Stein C.M. Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine 2009, 360:225-235.
30. Rouillon F., Chartier F., Gasquet I. Strategies of treatment with olanzapine in schizophrenic patients during stable phase: results of a pilot study. European Neuropsychopharmacology 2008, 18:646-652.
31. Clinical practice guidelines for the treatment of schizophrenia and related disorders 2004, Royal Australian and New Zealand College of Psychiatrists. http://www.ranzcp.org/images/stories/ranzcp-attachments/Resources/Publications/CPG/Clinician/CPG_Clinician_Full_Schizophrenia.pdf.
32. Schooler N.R. Maintenance medication for schizophrenia: strategies for dose reduction. Schizophrenia Bulletin 1991, 17:311-324.
33. Schooler N.R. Reducing dosage in maintenance treatment of schizophrenia. Review and prognosis. British Journal of Psychiatry 1993, 163(Suppl. 22):58-65.
34. Schooler N.R., Keith S.J., Severe J.B., Matthews S.M. Maintenance treatment of schizophrenia: a review of dose reduction and family treatment strategies. Psychiatric Quarterly 1995, 66:279-292.
35. Schooler N.R., Keith S.J., Severe J.B., Matthews S.M., Bellack A.S., Glick I.D., et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Archives of General Psychiatry 1997, 54:453-463.
36. Smith R.C. Lower-dose therapy with traditional neuroleptics in chronically hospitalized schizophrenic patients. Archives of General Psychiatry 1994, 51:427-429.
37. Suzuki T., Uchida H., Tanaka K.F., Tomita M., Tsunoda K., Nomura K., et al. Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. International Clinical Psychopharmacology 2003, 18:323-329.
38. Taylor D., Paton C., Kapur S. The Maudsley prescribing guidelines 2009, Informa Healthcare, London. 10th ed.
39. Uchida H., Suzuki T., Takeuchi H., Arenovich T., Mamo D.C. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophrenia Bulletin 2009, [Epub ahead of print].
40. Uchida H., Suzuki T., Takeuchi H., Mamo D.C. Increase in unfavorable treatment outcome with antipsychotic dose reduction: a hypothesis without convincing support. American Journal of Psychiatry 2010, 167:994.
41. Volavka J., Cooper T.B., Czobor P., Lindenmayer J.P., Citrome L.L., Mohr P., et al. High-dose treatment with haloperidol: the effect of dose reduction. Journal of Clinical Psychopharmacology 2000, 20:252-256.
42. Wang C.Y., Xiang Y.T., Cai Z.J., Weng Y.Z., Bo Q.J., Zhao J.P., et al. For the Risperidone Maintenance Treatment in Schizophrenia (RMTS) investigators. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. American Journal of Psychiatry 2010, 167:676-685.